Yaw Ansong-Ansongton, MDSickle Cell Disease | April 12, 2024
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
View More
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 9, 2024
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Erica Mamauag, MDHemophilia | April 9, 2024
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
Patrick DalyAnemia | April 5, 2024
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
Anjali Sharathkumar, MDAnemia | April 5, 2024
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
Zaina Inam, MDSickle Cell Disease | April 5, 2024
The study evaluated transplant outcomes in pediatric patients with SCD who had a history of red blood cell alloimmunization.
Patrick DalyAnemia | April 3, 2024
The European Commission approved an expanded indication for luspatercept as first-line therapy for anemia in lower-risk MDS.
Patrick DalySickle Cell Disease | April 4, 2024
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
Patrick DalyPNH | April 2, 2024
The US FDA has approved danicopan as an add-on therapy in patients with PNH and EVH on standard-of-care C5 inhibitor therapy.
Patrick DalyAnemia | March 29, 2024
The US FDA has approved vadadustat to treat anemia due to CKD in adults who have been on dialysis for at least three months.
Patrick DalyHemophilia | April 1, 2024
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.
Patrick DalyHematology | March 27, 2024
ASPHO President Caroline Hastings, MD, offers highlights from the 2024 ASPHO conference in Seattle, WA.
Melissa BadamoSickle Cell Disease | March 25, 2024
The two-year event-free survival was estimated to be 82.6%, and the two-year overall survival was 94.1%.
Patrick DalyAnemia | March 22, 2024
The US FDA ODAC voted that the benefits of imetelstat for managing anemia in lower-risk MDS outweigh the risks.
Patrick DalyVTE | March 22, 2024
Efficacy appeared to be similar among DOACs for managing cancer-related VTE, though apixaban may have more favorable safety.
Patrick DalyThrombosis | March 21, 2024
VRd was associated with lower rates of venous thromboembolism versus KRd in patients with newly-diagnosed multiple myeloma.
Patrick DalyPNH | March 20, 2024
Iptacopan monotherapy improved hematologic and clinical outcomes of persistent anemia in patients with PNH.
Melissa BadamoAnemia | March 18, 2024
The researchers evaluated surveys sent between 2015 and 2023 to patients with severe aplastic anemia who underwent HSCT.
Patrick DalyPNH | March 14, 2024
Dr. Griffin shares data from their real-world study on pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Patrick DalyMyelofibrosis | March 13, 2024
Study identifies risks of thrombosis, hemorrhage, and leukemic transformation in patients with myelofibrosis and other MPNs.
Latest News

April 12, 2024